ARS Pharmaceuticals (SPRY) Shares Outstanding (Weighted Average) (2020 - 2026)

ARS Pharmaceuticals has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $99.3 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $99.3 million, up 1.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $99.3 million (up 1.26% YoY), and the FY2025 annual result was $98.6 million, up 1.68% from the prior year.
• Shares Outstanding (Weighted Average) came in at $99.3 million for Q1 2026 at ARS Pharmaceuticals, up from $98.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $99.3 million in Q1 2026 to a low of $30.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $96.5 million (2024), against an average of $81.8 million.
• Across the five-year window, Shares Outstanding (Weighted Average) fell 12.67% in 2022 and soared 211.3% in 2023, its largest moves.
• ARS Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $40.0 million in 2022, then jumped by 138.3% to $95.2 million in 2023, then advanced by 1.81% to $96.9 million in 2024, then grew by 1.68% to $98.6 million in 2025, then grew by 0.74% to $99.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $99.3 million (Q1 2026), $98.6 million (Q4 2025), and $98.4 million (Q3 2025), per Business Quant data.